

SIDLEY AUSTIN LLP  
William E. Curtin (admitted *pro hac vice*)  
Anne G. Wallace (admitted *pro hac vice*)  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: wcurtin@sidley.com  
anne.wallace@sidley.com

SIDLEY AUSTIN LLP  
Thomas R. Califano (TX Bar No. 24122825)  
2021 McKinney Avenue, Suite 2000  
Dallas, Texas 75201  
Telephone: (214) 981-3300  
Facsimile: (214) 981-3400  
Email: tom.califano@sidley.com

*Attorneys for the Debtors  
and Debtors in Possession*

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**NOTICE OF FILING OF FOURTH PLAN SUPPLEMENT**

**PLEASE TAKE NOTICE THAT** on August 16, 2024, the Debtors filed the *Notice of Filing Plan Supplement* [Docket No. 525] (the “Initial Plan Supplement”), which was comprised of the following: (a) Liquidation Analysis; (b) Schedule of Assumed Executory Contracts and Unexpired Leases; (c) Schedule of Retained Causes of Action; (d) Amended Certificate of Incorporation of Eiger BioPharmaceuticals, Inc.; (e) Liquidating Trust Agreement; (f) Plan Administrator Agreement; and (g) Identity of Any Insider to Be Employed by the Plan Administrator;

**PLEASE TAKE FURTHER NOTICE THAT** on September 3, 2024, the Debtors filed the *Notice of Filing of Second Plan Supplement* [Docket No. 598] (the “Second Plan Supplement”).

**PLEASE TAKE FURTHER NOTICE THAT** on September 5, 2024, the United States Bankruptcy Court for the Northern District of Texas (the “Court”) entered the *Order Approving*

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Avenue, Dallas, Texas 75201.



*the Debtors' Amended Disclosure Statement and Confirming the Fifth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc. and its Debtor Affiliates* [Docket No. 639] (the "Confirmation Order") confirming the *Fifth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code* [Docket No. 635-1] (as may be altered, amended, modified, or supplemented from time to time, including all exhibits and schedules thereto, the "Plan").<sup>2</sup>

**PLEASE TAKE FURTHER NOTICE THAT** on September 27, 2024, the Debtors filed the *Notice of Filing of Third Plan Supplement* [Docket No. 679] (the "Third Plan Supplement").

**PLEASE TAKE FURTHER NOTICE THAT** the Debtors hereby file this fourth supplement to the Plan (together with the Initial Plan Supplement, the Second Plan Supplement, and the Third Plan Supplement, the "Plan Supplement"), consisting of the following documents:

<b>Exhibit</b>	<b>Fourth Plan Supplement Document</b>
B	Schedule of Assumed Executory Contracts and Unexpired Leases
B-1	Redline to Previously Filed Schedule of Assumed Executory Contracts and Unexpired Leases

**PLEASE TAKE FURTHER NOTICE THAT** the Debtors reserve the right to alter, amend, modify, or supplement any document in the Plan Supplement in accordance with the Plan; *provided* that if any document in the Plan Supplement is altered, amended, modified, or supplemented in any material respect prior to the date of the Combined Hearing, the Debtors will promptly file a redline of such document with the Court.

**PLEASE TAKE FURTHER NOTICE THAT** if you would like to obtain a copy of the Confirmation Order, the Plan, the Plan Supplement, or related documents, such materials are available free of charge by: (a) accessing the Debtors' restructuring website at <https://www.veritaglobal.net/Eiger>; (b) writing to Eiger Ballot Processing Center, c/o Kurtzman Carson Consultants, LLC, dba Verita, 222 N. Pacific Coast Highway, Suite 300, El Segundo, California 90245; (c) calling (888) 733-1544 (U.S. and Canada toll free) or (310) 751-2638 (international); or (d) submitting an inquiry via online form at <https://www.veritaglobal.net/Eiger/inquiry>. You may also obtain copies of any pleadings filed in these chapter 11 cases for a fee via PACER at <https://ecf.txnb.uscourts.gov/>.

---

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Plan.

Dated: September 30, 2024  
Dallas, Texas

**SIDLEY AUSTIN LLP**

*/s/ Thomas R. Califano*

---

Thomas R. Califano (TX Bar No. 24122825)  
2021 McKinney Avenue, Suite 2000  
Dallas, Texas 75201  
Telephone: (214) 981-3300  
Facsimile: (214) 981-3400  
Email: tom.califano@sidley.com

*and*

William E. Curtin (admitted *pro hac vice*)  
Anne G. Wallace (admitted *pro hac vice*)  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: wcurtin@sidley.com  
anne.wallace@sidley.com

*Attorneys for the Debtors and Debtors in  
Possession*

**Certificate of Service**

I certify that on September 30, 2024, I caused a copy of the foregoing document to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Northern District of Texas.

*/s/ Thomas R. Califano*

---

Thomas R. Califano

**Exhibit B**

**Schedule of Assumed Executory Contracts and Unexpired Leases<sup>1</sup>**

The inclusion of a contract or other agreement in the following Schedule of Assumed Executory Contracts and Unexpired Leases shall not constitute or be deemed a determination or admission by the Debtors and their Estates or any other party in interest that such contract or other agreement is, in fact, an Executory Contract or Unexpired Lease within the meaning of the Bankruptcy Code, and any and all rights of the Debtors and their Estates, the Wind-Down Debtors and their Estates, the Plan Administrator, or the Liquidating Trustee with respect thereto are hereby reserved. Unless otherwise specified, each contract or other agreement listed herein shall include all exhibits, schedules, confirmations, riders, modifications, declarations, amendments, supplements, attachments, restatements, or other agreements made directly or indirectly by any agreement, instrument, or other document that in any manner affects such contract or other agreement, without respect to whether such agreement, instrument, or other document is listed herein. The Debtors reserve all rights to amend, revise, or supplement the Schedule of Assumed Executory Contracts and Unexpired Leases, and any of the documents and designations contained herein.

---

<sup>1</sup> Capitalized terms used herein shall have the meaning ascribed to them in the *Fifth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code* [Docket No. 635-1] (as may be amended, supplemented, or modified from time to time, the “Plan”).

**Eiger Biopharmaceuticals, Inc.**

Contract Assumption List

Sort #	Counterparty	Description of Contract	Cure Amounts	
344	Accenture LLP	MSA	\$5,399.00	
345	Accenture LLP	SOW 1		
346	Accenture LLP	Software License		
347	Accenture LLP	SOW 2		
348	Accenture LLP	SOW 3		
349	Accenture LLP	Change Order 1 to SOW 2		
350	Accenture LLP	Change Order 1 to SOW 3		
351	Accenture LLP	Change Order 2 to SOW 5		
352	Accenture LLP	Amended and Restated SOW 5		
353	Accenture LLP	Change Order 2 to Amended and Restated SOW 5		
354	Accenture LLP	Data Privacy and Security Exhibit		
355	Accenture LLP	Amendment 1 to MSA		
356	Accenture LLP	Change Order 2 to SOW 3		
357	Accenture LLP	SOW 7		
358	Accenture LLP	Change Order 1 to SOW 8		
326	Box, Inc.	License Renewal Q-00288262		\$0.00
403	Bend Research, Inc. (LONZA)	Commercial Manufacturing Services and Supply Agreement with Bend Research, Inc. (LONZA) dated October 9, 2019		\$0.00
339	Browneinc dba BrowneMusser	MSA	\$0.00	
340	Browneinc dba BrowneMusser	Work Order #1	\$0.00	
305	Countsy	AP Outsourcing	\$0.00	
328	CrossCountry Consulting LLC	PPS Project Order 3	\$3,024.00	
408	Corden Pharma Colorado, LLC	Commercial Quality Agreement with Corden Pharma Colorado, LLC	\$0.00	
404	CordenPharma	Master Services Agreement with CordenPharma dated February 2016	\$0.00	
341	Digital Media Innovations, LLC	Notified Order Form 00098976	\$5,600.00	
322	Jump Start Technology, Inc.	Quote JSTQ2145	\$17,203.75	
330	Jump Start Technology, Inc.	Services Agreement		
301	JumpStart Technology	SOW (Sox Compliance)		
406	Fisher Clinical Services, Inc.	First Amendment and Restated Quality Agreement with Fisher Clinical Services, Inc.	\$0.00	
401	Fisher Clinical Services, Inc.	Master Services Agreement with Fisher Clinical Services, Inc. dated May 6, 2016	\$0.00	

332	Niche Quality Limited	CNS	\$1,866.24
333	Niche Quality Limited	Quote 1092047	
318	Okta	Quote Q-545757	\$0.00
307	Okta, Inc	Quote Q-368834	\$0.00
400	Oracle America Inc	Estimate 1316870	\$0.00
405	Lonza Bend, Inc.	Quality Agreement with Lonza Bend, Inc.	\$0.00
402	Patheon, Inc.	Master Manufacturing Services Agreement with Patheon, Inc. dated January 9, 2020	\$0.00
407	Patheon, Inc.	Quality Agreement with Patheon, Inc.	\$0.00
325	PhaseIII LLC	CNS	\$0.00
324	Precision Trials Solutions LLC	CNS	\$0.00
331	Regus CME Ireland Ltd	Lease	\$4,240.76
310	TriNet	Addendum	\$0.00
314	TriNet and Washington State	Auth to Access or File	\$0.00
329	ZenQMS LLC	SOW	\$0.00
	IQVIA RDS INC.	Work Order #KZA43736, dated May 8, 2019	\$1,663,071.67
	IQVIA RDS INC.	Change Order 1 to WO #KZA43736, dated March 26, 2020	
	IQVIA RDS INC.	General Services Agreement for Emerging Biotech Clients, dated October 15, 2018	
	IQVIA RDS INC.	Change Order 3 to MZA58497	
	IQVIA RDS INC.	Change Order 5 to MZA58497	
	IQVIA Biotech LLC	Change Proposal No. 1	
	IQVIA Biotech LLC	Change Notification No. 1	
	IQVIA Biotech LLC	Change Notification No. 2	
	IQVIA Biotech LLC	Change Notification No. 3	
	IQVIA Biotech LLC	Change Notification No. 4	
	IQVIA Biotech LLC	Change Proposal No. 15	
	Novella Clinical LLC	Master Services Agreement, dated January 15, 2016 ("Novella MSA Jan 15 2016")	
	Novella Clinical LLC	Statement of Work, dated April 8, 2016	
	Novella Clinical LLC	Statement of Work, dated July 19, 2016	
	Novella Clinical LLC	Change Proposal 1	
	Novella Clinical LLC	Change Proposal 2	
	Novella Clinical LLC	Change Proposal 3	
	Novella Clinical LLC	Change Proposal 4	
	Novella Clinical LLC	Change Proposal 5	
	Novella Clinical LLC	Change Proposal 6	
	Novella Clinical LLC	Change Proposal 7	
	Novella Clinical LLC	Change Proposal 8	

**Exhibit B-1**

**Redline to Previously Filed Schedule of Assumed Executory Contracts and Unexpired  
Leases**



## **Exhibit B**

### **Schedule of Assumed Executory Contracts and Unexpired Leases<sup>1</sup>**

The inclusion of a contract or other agreement in the following Schedule of Assumed Executory Contracts and Unexpired Leases shall not constitute or be deemed a determination or admission by the Debtors and their Estates or any other party in interest that such contract or other agreement is, in fact, an Executory Contract or Unexpired Lease within the meaning of the Bankruptcy Code, and any and all rights of the Debtors and their Estates, the Wind-Down Debtors and their Estates, the Plan Administrator, or the Liquidating Trustee with respect thereto are hereby reserved. Unless otherwise specified, each contract or other agreement listed herein shall include all exhibits, schedules, confirmations, riders, modifications, declarations, amendments, supplements, attachments, restatements, or other agreements made directly or indirectly by any agreement, instrument, or other document that in any manner affects such contract or other agreement, without respect to whether such agreement, instrument, or other document is listed herein. The Debtors reserve all rights to amend, revise, or supplement the Schedule of Assumed Executory Contracts and Unexpired Leases, and any of the documents and designations contained herein.

<sup>1</sup> Capitalized terms used herein shall have the meaning ascribed to them in the ~~Third~~Fifth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code [Docket No. ~~571-1~~635-1] (as may be amended, supplemented, or modified from time to time, the “Plan”).

**Eiger Biopharmaceuticals, Inc.**

Contract Assumption List

Sort #	Counterparty	Description of Contract	Cure Amounts
344	Accenture LLP	MSA	\$5,399.00
345	Accenture LLP	SOW 1	
346	Accenture LLP	Software License	
347	Accenture LLP	SOW 2	
348	Accenture LLP	SOW 3	
349	Accenture LLP	Change Order 1 to SOW 2	
350	Accenture LLP	Change Order 1 to SOW 3	
351	Accenture LLP	Change Order 2 to SOW 5	
352	Accenture LLP	Amended and Restated SOW 5	
353	Accenture LLP	Change Order 2 to Amended and Restated SOW 5	
354	Accenture LLP	Data Privacy and Security Exhibit	
355	Accenture LLP	Amendment 1 to MSA	
356	Accenture LLP	Change Order 2 to SOW 3	
357	Accenture LLP	SOW 7	
358	Accenture LLP	Change Order 1 to SOW 8	
326	Box, Inc.	License Renewal Q-00288262	
403	Bend Research, Inc. (LONZA)	Commercial Manufacturing Services and Supply Agreement with Bend Research, Inc. (LONZA) dated October 9, 2019	\$0.00
339	Browneinc dba BrowneMusser	MSA	\$0.00
340	Browneinc dba BrowneMusser	Work Order #1	\$0.00
305	Countsy	AP Outsourcing	\$0.00
328	CrossCountry Consulting LLC	PPS Project Order 3	\$3,024.00
408	Corden Pharma Colorado, LLC	Commercial Quality Agreement with Corden Pharma Colorado, LLC	\$0.00
404	CordenPharma	Master Services Agreement with CordenPharma dated February 2016	\$0.00
341	Digital Media Innovations, LLC	Notified Order Form 00098976	\$5,600.00
322	Jump Start Technology, Inc.	Quote JSTQ2145	\$17,203.75
330	Jump Start Technology, Inc.	Services Agreement	
301	JumpStart Technology	SOW (Sox Compliance)	
406	Fisher Clinical Services, Inc.	First Amendment and Restated Quality Agreement with Fisher Clinical Services, Inc.	\$0.00
401	Fisher Clinical Services, Inc.	Master Services Agreement with Fisher Clinical Services, Inc. dated May 6, 2016	\$0.00
332	Niche Quality Limited	CNS	\$1,866.24
333	Niche Quality Limited	Quote 1092047	

318	Okta	Quote Q-545757	\$0.00
307	Okta, Inc	Quote Q-368834	\$0.00
400	Oracle America Inc	Estimate 1316870	\$0.00
405	Lonza Bend, Inc.	Quality Agreement with Lonza Bend, Inc.	\$0.00
402	Patheon, Inc.	Master Manufacturing Services Agreement with Patheon, Inc. dated January 9, 2020	\$0.00
407	Patheon, Inc.	Quality Agreement with Patheon, Inc.	\$0.00
325	PhaseIII LLC	CNS	\$0.00
324	Precision Trials Solutions LLC	CNS	\$0.00
331	Regus CME Ireland Ltd	Lease	\$4,240.76
310	TriNet	Addendum	\$0.00
314	TriNet and Washington State	Auth to Access or File	\$0.00
329	ZenQMS LLC	SOW	\$0.00
	<a href="#">IQVIA RDS INC.</a>	<a href="#">Work Order #KZA43736, dated May 8, 2019</a>	<a href="#">\$1,663,071.67</a>
	<a href="#">IQVIA RDS INC.</a>	<a href="#">Change Order 1 to WO #KZA43736, dated March 26, 2020</a>	
	<a href="#">IQVIA RDS INC.</a>	<a href="#">General Services Agreement for Emerging Biotech Clients, dated October 15, 2018</a>	
	<a href="#">IQVIA RDS INC.</a>	<a href="#">Change Order 3 to MZA58497</a>	
	<a href="#">IQVIA RDS INC.</a>	<a href="#">Change Order 5 to MZA58497</a>	
	<a href="#">IQVIA Biotech LLC</a>	<a href="#">Change Proposal No. 1</a>	
	<a href="#">IQVIA Biotech LLC</a>	<a href="#">Change Notification No. 1</a>	
	<a href="#">IQVIA Biotech LLC</a>	<a href="#">Change Notification No. 2</a>	
	<a href="#">IQVIA Biotech LLC</a>	<a href="#">Change Notification No. 3</a>	
	<a href="#">IQVIA Biotech LLC</a>	<a href="#">Change Notification No. 4</a>	
	<a href="#">IQVIA Biotech LLC</a>	<a href="#">Change Proposal No. 15</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Master Services Agreement, dated January 15, 2016 ("Novella MSA Jan 15 2016")</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Statement of Work, dated April 8, 2016</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Statement of Work, dated July 19, 2016</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 1</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 2</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 3</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 4</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 5</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 6</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 7</a>	
	<a href="#">Novella Clinical LLC</a>	<a href="#">Change Proposal 8</a>	